[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Miyake
Kazumasa
K
Third Department of Internal Medicine, Nippon Medical School.
Sakamoto
Choitsu
C
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D016503:Drug Delivery Systems; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000008:administration & dosage; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D007783:Lactones; D008565:Membrane Proteins; D009288:Naproxen; D009853:Omeprazole / Q000008:administration & dosage; D010437:Peptic Ulcer / Q000209:etiology* / Q000517:prevention & control*; D011451:Prostaglandin-Endoperoxide Synthases; D054328:Proton Pump Inhibitors; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D054328:Proton Pump Inhibitors; D013450:Sulfones; C116926:rofecoxib; D009288:Naproxen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D009853:Omeprazole